Barclays
VRCA icon

Barclays’s Verrica Pharmaceuticals VRCA Stock Holding History

Barclays’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392 Buy
+64
New +$399 ﹤0.01% 5041
2026
Q1 		– Sell
-1
Closed -$8 – 5468
2025
Q4 		$8 Hold
1
– – ﹤0.01% 5160
2025
Q3 		$4 Sell
1
-1
-50% -$6 ﹤0.01% 5420
2025
Q2 		$8 Sell
2
-4,436
-100% -$23.9K ﹤0.01% 5160
2025
Q1 		$19.6K Buy
4,438
+1,437
+48% +$9.29K ﹤0.01% 4794
2024
Q4 		$21K Sell
3,001
-133
-4% -$1.46K ﹤0.01% 4918
2024
Q3 		$45.4K Buy
3,134
+2,513
+405% +$113K ﹤0.01% 4767
2024
Q2 		$45.3K Sell
621
-838
-57% -$64.4K ﹤0.01% 4243
2024
Q1 		$86.4K Sell
1,459
-1,405
-49% -$77.6K ﹤0.01% 4479
2023
Q4 		$210K Buy
2,864
+2,501
+689% +$103K ﹤0.01% 4397
2023
Q3 		$14.1K Sell
363
-54
-13% -$2.74K ﹤0.01% 4247
2023
Q2 		$24.1K Sell
417
-1,275
-75% -$77.4K ﹤0.01% 4095
2023
Q1 		$110K Buy
+1,692
New +$102K ﹤0.01% 4121
2022
Q2 		– Sell
-213
Closed -$17K – 5289
2022
Q1 		$17K Sell
213
-1,377
-87% -$113K ﹤0.01% 4487
2021
Q4 		$146K Buy
1,590
+1,055
+197% +$119K ﹤0.01% 3648
2021
Q3 		$67K Buy
535
+364
+213% +$40.8K ﹤0.01% 4043
2021
Q2 		$20K Sell
171
-869
-84% -$105K ﹤0.01% 4500
2021
Q1 		$157K Buy
1,040
+638
+159% +$88.3K ﹤0.01% 3814
2020
Q4 		$46K Sell
402
-175
-30% -$16.1K ﹤0.01% 4444
2020
Q3 		$44K Sell
577
-113
-16% -$9.26K ﹤0.01% 4663
2020
Q2 		$76K Buy
690
+263
+62% +$30.4K ﹤0.01% 4702
2020
Q1 		$46K Sell
427
-863
-67% -$114K ﹤0.01% 5276
2019
Q4 		$205K Buy
1,290
+654
+103% +$96.5K ﹤0.01% 5011
2019
Q3 		$94K Sell
636
-195
-23% -$21.7K ﹤0.01% 5525
2019
Q2 		$97K Buy
831
+374
+82% +$35.1K ﹤0.01% 5718
2019
Q1 		$50K Buy
+457
New +$52.7K ﹤0.01% 5875
2018
Q4 		– Sell
-217
Closed -$35K – 7372
2018
Q3 		$35K Buy
+217
New +$37.1K ﹤0.01% 6258

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's VRCA Position: Q2 2026 in Review

Barclays opened a new position in Verrica Pharmaceuticals (VRCA) in Q2 2026: 64 shares worth $392. The stake represents ﹤0.01% of the portfolio and ranks #5041 among its holdings. This is a return to the name: Barclays previously reported a position in VRCA as recently as Q4 2025.

Barclays first reported a position in VRCA in Q3 2018 and has held it in 27 quarters since. The position peaked at $210K in Q4 2023. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Barclays held 64 shares of Verrica Pharmaceuticals worth $392 as of Q2 2026.
  • Verrica Pharmaceuticals was a new Barclays position in Q2 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5041 holding.
  • Barclays first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
  • Barclays's Verrica Pharmaceuticals position peaked at $210K in Q4 2023.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.